000165825 001__ 165825
000165825 005__ 20240229123210.0
000165825 0247_ $$2doi$$a10.3390/cancers12113254
000165825 0247_ $$2pmid$$apmid:33158149
000165825 0247_ $$2altmetric$$aaltmetric:95273529
000165825 037__ $$aDKFZ-2020-02405
000165825 041__ $$aeng
000165825 082__ $$a610
000165825 1001_ $$00000-0003-0938-1543$$aBrandão, Andreia$$b0
000165825 245__ $$aThe CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.
000165825 260__ $$aBasel$$bMDPI$$c2020
000165825 3367_ $$2DRIVER$$aarticle
000165825 3367_ $$2DataCite$$aOutput Types/Journal article
000165825 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1604917490_25264
000165825 3367_ $$2BibTeX$$aARTICLE
000165825 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165825 3367_ $$00$$2EndNote$$aJournal Article
000165825 520__ $$aThe identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.
000165825 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000165825 588__ $$aDataset connected to CrossRef, PubMed,
000165825 7001_ $$aPaulo, Paula$$b1
000165825 7001_ $$aMaia, Sofia$$b2
000165825 7001_ $$aPinheiro, Manuela$$b3
000165825 7001_ $$aPeixoto, Ana$$b4
000165825 7001_ $$aCardoso, Marta$$b5
000165825 7001_ $$aSilva, Maria P$$b6
000165825 7001_ $$aSantos, Catarina$$b7
000165825 7001_ $$00000-0002-3698-6241$$aEeles, Rosalind A$$b8
000165825 7001_ $$aKote-Jarai, Zsofia$$b9
000165825 7001_ $$00000-0001-6429-988X$$aMuir, Kenneth$$b10
000165825 7001_ $$aUkgpcs Collaborators$$b11
000165825 7001_ $$00000-0002-1863-0305$$aSchleutker, Johanna$$b12
000165825 7001_ $$00000-0002-1241-6252$$aWang, Ying$$b13
000165825 7001_ $$00000-0003-0843-2468$$aPashayan, Nora$$b14
000165825 7001_ $$aBatra, Jyotsna$$b15
000165825 7001_ $$aApcb BioResource$$b16
000165825 7001_ $$aGrönberg, Henrik$$b17
000165825 7001_ $$aNeal, David E$$b18
000165825 7001_ $$00000-0002-1954-7220$$aNordestgaard, Børge G$$b19
000165825 7001_ $$aTangen, Catherine M$$b20
000165825 7001_ $$aSouthey, Melissa C$$b21
000165825 7001_ $$aWolk, Alicja$$b22
000165825 7001_ $$aAlbanes, Demetrius$$b23
000165825 7001_ $$aHaiman, Christopher A$$b24
000165825 7001_ $$aTravis, Ruth C$$b25
000165825 7001_ $$aStanford, Janet L$$b26
000165825 7001_ $$aMucci, Lorelei A$$b27
000165825 7001_ $$aWest, Catharine M L$$b28
000165825 7001_ $$aNielsen, Sune F$$b29
000165825 7001_ $$aKibel, Adam S$$b30
000165825 7001_ $$aCussenot, Olivier$$b31
000165825 7001_ $$aBerndt, Sonja I$$b32
000165825 7001_ $$aKoutros, Stella$$b33
000165825 7001_ $$00000-0002-4902-5490$$aSørensen, Karina Dalsgaard$$b34
000165825 7001_ $$00000-0002-2819-3057$$aCybulski, Cezary$$b35
000165825 7001_ $$aGrindedal, Eli Marie$$b36
000165825 7001_ $$aPark, Jong Y$$b37
000165825 7001_ $$aIngles, Sue A$$b38
000165825 7001_ $$aMaier, Christiane$$b39
000165825 7001_ $$aHamilton, Robert J$$b40
000165825 7001_ $$aRosenstein, Barry S$$b41
000165825 7001_ $$aVega, Ana$$b42
000165825 7001_ $$aThe Impact Study Steering Committee And Collaborators$$b43
000165825 7001_ $$aKogevinas, Manolis$$b44
000165825 7001_ $$00000-0002-4623-0544$$aWiklund, Fredrik$$b45
000165825 7001_ $$aPenney, Kathryn L$$b46
000165825 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b47$$udkfz
000165825 7001_ $$aJohn, Esther M$$b48
000165825 7001_ $$aKaneva, Radka$$b49
000165825 7001_ $$aLogothetis, Christopher J$$b50
000165825 7001_ $$aNeuhausen, Susan L$$b51
000165825 7001_ $$aRuyck, Kim De$$b52
000165825 7001_ $$aRazack, Azad$$b53
000165825 7001_ $$aNewcomb, Lisa F$$b54
000165825 7001_ $$aCanary Pass Investigators$$b55
000165825 7001_ $$00000-0003-4496-244X$$aLessel, Davor$$b56
000165825 7001_ $$aUsmani, Nawaid$$b57
000165825 7001_ $$aClaessens, Frank$$b58
000165825 7001_ $$00000-0001-6713-4351$$aGago-Dominguez, Manuela$$b59
000165825 7001_ $$aTownsend, Paul A$$b60
000165825 7001_ $$00000-0001-6967-1708$$aRoobol, Monique J$$b61
000165825 7001_ $$aThe Profile Study Steering Committee$$b62
000165825 7001_ $$aThe Practical Consortium$$b63
000165825 7001_ $$00000-0002-4896-5982$$aTeixeira, Manuel R$$b64
000165825 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12113254$$gVol. 12, no. 11, p. 3254 -$$n11$$p3254$$tCancers$$v12$$x2072-6694$$y2020
000165825 909CO $$ooai:inrepo02.dkfz.de:165825$$pVDB
000165825 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b47$$kDKFZ
000165825 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000165825 9141_ $$y2020
000165825 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000165825 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000165825 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000165825 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000165825 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000165825 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000165825 980__ $$ajournal
000165825 980__ $$aVDB
000165825 980__ $$aI:(DE-He78)C070-20160331
000165825 980__ $$aI:(DE-He78)C120-20160331
000165825 980__ $$aI:(DE-He78)HD01-20160331
000165825 980__ $$aUNRESTRICTED